Page 58 - Read Online

Morgan et al. HOX genes and the tumor microenvironment

71. Zhu F, Liu P, Li J, Zhang Y. Eotaxin-1 promotes prostate cancer cell PE, Hu JJ, Ochoa AC. Cytokine genetic polymorphisms and prostate
invasion via activation of the CCR3-ERK pathway and upregulation cancer aggressiveness. Carcinogenesis 2009;30:1358-62.
of MMP-3 expression. Oncol Rep 2014;31:2049-54. 90. Carbone C, Tamburrino A, Piro G, Boschi F, Cataldo I, Zanotto
72. Srivastava P, Kapoor R, Mittal RD. Impact of MMP-3 and TIMP-3 M, Mina MM, Zanini S, Sbarbati A, Scarpa A, Tortora G, Melisi
gene polymorphisms on prostate cancer susceptibility in North Indian D. Combined inhibition of IL1, CXCR1/2, and TGFbeta signaling
cohort. Gene 2013;530:273-7. pathways modulates in-vivo resistance to anti-VEGF treatment.
73. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal Anticancer Drugs 2016;27:29-40.
transition. J Clin Invest 2009;119:1420-8. 91. Wei ZW, Xia GK, Wu Y, Chen W, Xiang Z, Schwarz RE, Brekken
74. Grant CM, Kyprianou N. Epithelial mesenchymal transition (EMT) RA, Awasthi N, He YL, Zhang CH. CXCL1 promotes tumor growth
in prostate growth and tumor progression. Transl Androl Urol through VEGF pathway activation and is associated with inferior
2013;2:202-11. survival in gastric cancer. Cancer Lett 2015;359:335-43.
75. Shaoqiang C, Yue Z, Yang L, Hong Z, Lina Z, Da P, Qingyuan Z. 92. Wilson C, Scullin P, Worthington J, Seaton A, Maxwell P, O’Rourke D,
Expression of HOXD3 correlates with shorter survival in patients with Johnston PG, McKeown SR, Wilson RH, O’Sullivan JM, Waugh DJ.
invasive breast cancer. Clin Exp Metastasis 2013;30:155-63. Dexamethasone potentiates the antiangiogenic activity of docetaxel in
76. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier castration-resistant prostate cancer. Br J Cancer 2008;99:2054-64.
G, Cheresh DA. Integrin alpha v beta 3 antagonists promote tumor 93. Kuo PL, Shen KH, Hung SH, Hsu YL. CXCL1/GROalpha increases
regression by inducing apoptosis of angiogenic blood vessels. Cell cell migration and invasion of prostate cancer by decreasing fibulin-1
1994;79:1157-64. expression through NF-kappaB/HDAC1 epigenetic regulation.
77. Pidgeon GP, Tang K, Cai YL, Piasentin E, Honn KV. Overexpression Carcinogenesis 2012;33:2477-87.
of platelet-type 12-lipoxygenase promotes tumor cell survival by 94. Pecot CV, Rupaimoole R, Yang D, Akbani R, Ivan C, Lu C, Wu S,
enhancing alpha(v)beta(3) and alpha(v)beta(5) integrin expression. Han HD, Shah MY, Rodriguez-Aguayo C, Bottsford-Miller J, Liu Y,
Cancer Res 2003;63:4258-67. Kim SB, Unruh A, Gonzalez-Villasana V, Huang L, Zand B, Moreno-
78. Teitelbaum SL. Osteoclasts and integrins. Ann N Y Acad Sci Smith M, Mangala LS, Taylor M, Dalton HJ, Sehgal V, Wen Y, Kang
2006;1068:95-9. Y, Baggerly KA, Lee JS, Ram PT, Ravoori MK, Kundra V, Zhang X,
79. Dresner-Pollak R, Rosenblatt M. Blockade of osteoclast-mediated Ali-Fehmi R, Gonzalez-Angulo AM, Massion PP, Calin GA, Lopez-
bone resorption through occupancy of the integrin receptor: a Berestein G, Zhang W, Sood AK. Tumour angiogenesis regulation by
potential approach to the therapy of osteoporosis. J Cell Biochem the miR-200 family. Nat Commun 2013;4:2427.
1994;56:323-30. 95. Dumont DJ, Gradwohl G, Fong GH, Puri MC, Gertsenstein M,
80. Rosenthal MA, Davidson P, Rolland F, Campone M, Xue L, Han Auerbach A, Breitman ML. Dominant-negative and targeted
TH, Mehta A, Berd Y, He W, Lombardi A. Evaluation of the safety, null mutations in the endothelial receptor tyrosine kinase, tek,
pharmacokinetics and treatment effects of an alpha(nu)beta(3) integrin reveal a critical role in vasculogenesis of the embryo. Genes Dev
inhibitor on bone turnover and disease activity in men with hormone- 1994;8:1897-909.
refractory prostate cancer and bone metastases. Asia Pac J Clin Oncol 96. Sato TN, Tozawa Y, Deutsch U, Wolburg-Buchholz K, Fujiwara Y,
2010;6:42-8. Gendron-Maguire M, Gridley T, Wolburg H, Risau W, Qin Y. Distinct
81. Jayson GC, Kerbel R, Ellis LM, Harris AL. Antiangiogenic roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel
therapy in oncology: current status and future directions. Lancet formation. Nature 1995;376:70-4.
2016;388:518-29. 97. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis
82. Boudreau NJ, Varner JA. The homeobox transcription factor Hox S, Sato TN, Yancopoulos GD. Requisite role of angiopoietin-1, a
D3 promotes integrin alpha5beta1 expression and function during ligand for the TIE2 receptor, during embryonic angiogenesis. Cell
angiogenesis. J Biol Chem 2004;279:4862-8. 1996;87:1171-80.
83. Arderiu G, Cuevas I, Chen A, Carrio M, East L, Boudreau NJ. HoxA5 98. Satoh N, Yamada Y, Kinugasa Y, Takakura N. Angiopoietin-1
stabilizes adherens junctions via increased Akt1. Cell Adh Migr alters tumor growth by stabilizing blood vessels or by promoting
2007;1:185-95. angiogenesis. Cancer Sci 2008;99:2373-9.
84. Rhoads K, Arderiu G, Charboneau A, Hansen SL, Hoffman W, 99. Rossig L, Urbich C, Bruhl T, Dernbach E, Heeschen C, Chavakis E,
Boudreau N. A role for Hox A5 in regulating angiogenesis and Sasaki K, Aicher D, Diehl F, Seeger F, Potente M, Aicher A, Zanetta
vascular patterning. Lymphat Res Biol 2005;3:240-52. L, Dejana E, Zeiher AM, Dimmeler S. Histone deacetylase activity is
85. Care A, Silvani A, Meccia E, Mattia G, Stoppacciaro A, Parmiani essential for the expression of HoxA9 and for endothelial commitment
G, Peschle C, Colombo MP. HOXB7 constitutively activates basic of progenitor cells. J Exp Med 2005;201:1825-35.
fibroblast growth factor in melanomas. Mol Cell Biol 1996;16:4842-51. 100. Boudreau N, Andrews C, Srebrow A, Ravanpay A, Cheresh DA.
86. Matsuo M, Yamada S, Koizumi K, Sakurai H, Saiki I. Tumour-derived Induction of the angiogenic phenotype by Hox D3. J Cell Biol
fibroblast growth factor-2 exerts lymphangiogenic effects through 1997;139:257-64.
Akt/mTOR/p70S6kinase pathway in rat lymphatic endothelial cells. 101. Wheler JJ, Janku F, Falchook GS, Jackson TL, Fu S, Naing A,
Eur J Cancer 2007;43:1748-54. Tsimberidou AM, Moulder SL, Hong DS, Yang H, Piha-Paul SA,
87. Huang S, Mills L, Mian B, Tellez C, McCarty M, Yang XD, Gudas JM, Atkins JT, Garcia-Manero G, Kurzrock R. Phase I study of anti-VEGF
Bar-Eli M. Fully humanized neutralizing antibodies to interleukin-8 monoclonal antibody bevacizumab and histone deacetylase inhibitor
(ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of valproic acid in patients with advanced cancers. Cancer Chemother
human melanoma. Am J Pathol 2002;161:125-34. Pharmacol 2014;73:495-501.
88. Martin D, Galisteo R, Gutkind JS. CXCL8/IL8 stimulates vascular 102. Devy L, Blacher S, Grignet-Debrus C, Bajou K, Masson V, Gerard
endothelial growth factor (VEGF) expression and the autocrine RD, Gils A, Carmeliet G, Carmeliet P, Declerck PJ, Noel A, Foidart
activation of VEGFR2 in endothelial cells by activating NFkappaB JM. The pro- or antiangiogenic effect of plasminogen activator
through the CBM (Carma3/Bcl10/Malt1) complex. J Biol Chem inhibitor 1 is dose dependent. FASEB J 2002;16:147-54.
2009;284:6038-42. 103. Montuori N, Ragno P. Role of uPA/uPAR in the modulation of
89. Zabaleta J, Su LJ, Lin HY, Sierra RA, Hall MC, Sartor AO, Clark angiogenesis. Chem Immunol Allergy 2014;99:105-22.
286 Journal of Cancer Metastasis and Treatment ¦ Volume 3 ¦ December 6, 2017